Artificial intelligence, machine learning. Biostat programmers have created a Drug Assistant function in the Medfile electronic medical documentation software. This is nothing more than a mathematical model based on artificial intelligence. This solution significantly facilitates and supports the work of doctors and medical professionals.

The Biostat Research and Development Center has been successfully developing its proprietary electronic medical documentation software, Medfile, for several years. Currently, Medfile is one of the most preferred applications in medical offices and clinics, and the program continuously adds advanced features to make the work of doctors and medical staff more manageable.

In October of this year, Medfile users gained access to another tool – the Drug Assistant, a virtual medication assistant. Biostat programmers utilized artificial intelligence to create this function.

- The Drug Assistant in Medfile is nothing more than a mathematical model based on artificial intelligence. This virtual assistant supports the doctor in the process of prescribing e-prescriptions. Based on previous behavior, the system suggests other drugs related in some way to the initial selection made by the doctor. For example, if the first drug chosen by the doctor is an antibiotic, a complementary medication may be suggested

- explains Tomasz Kusy, Research Development Manager at Biostat.

Tomasz Kusy emphasizes that the algorithm created is not intended to replace the doctor but rather to assist medical professionals in the drug selection process. The described mechanism is only a small fraction of the Drug Assistant's capabilities. In the subsequent stages of this project's development, the system will be able to utilize analysis and information from the ICD-10 classification, the behavior of different doctors in the area of a specific diagnosis, and drug interactions.

Biostat's CEO, Rafał Piszczek, highlights that the Drug Assistant tool in Medfile is just one of the projects within the Biostat group that utilize artificial intelligence in medical software.

- For many years, it has been known that machine learning and artificial intelligence are the future of healthcare in the broadest sense. That's why we consistently invest in the development of our R&D department and AI-based solutions and software

- says Rafał Piszczek.

President Piszczek adds that Biostat is not limited to research and development work in the Polish market. Soon, we will provide information about pilot studies conducted by our team in the Norwegian market in the area of Digital Twin.